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Abstract: Background: The effects of drugs on driving performance should be checked with drug 
concentration in the brain and at the same time with the evaluation of both the behavioural and neu-
rophysiological effects. The best accessible indicator of this information is the concentration of the 
drug and/or metabolites in blood and, to a certain extent, oral fluid. We sought to review interna-
tional studies on correlation between blood and oral fluid drug concentrations, neurological corre-
lates and cognitive impairment in driving under the influence of drugs. 
Methods: Relevant scientific articles were identified from PubMed, Cochrane Central, Scopus, 
Web of Science, Science Direct, EMBASE up to April 2017. 
Results: Up to 2010, no epidemiological studies were available on this matter and International 
scientists suggested that even minimal amounts of parent drugs in blood and oral fluid could affect 
driving impairment. More recently, epidemiological data, systematic reviews and meta-analysis on 
drugged drivers allowed the suggestion of impairment concentration limits for the most common 
illicit drugs. These values were obtained comparing driving disability induced by psychotropic 
drugs with that of established blood alcohol limits. Differently from ethyl alcohol where both detec-
tion methods and concentration limits have been well established even with inhomogeneity of 
ranges within different countries, in case of drugs of abuse no official cut-offs have yet been estab-
lished, nor any standardized analytical protocols. 
Conclusion: Multiple aspects of driving performance can be differently affected by illicit drugs, 
and even if for few of them some dose/concentration dependent impairment has been reported, a 
wider knowledge on concentration/impairment relationship is still missing. 
Keywords: Cognitive impairment, driving under the influence of drugs (DUID), blood, oral fluid, cut-off. 
INTRODUCTION 
 A recent report by The World Health Organization on 
road safety showed that in 2013, 3.16% and 15.03% of total 
road traffic deaths have been related to psychoactive drug 
use or alcohol consumption, respectively [1]. The association 
between alcohol drinking, impaired driving, and road acci-
dents risk has been extensively investigated, leading to offi-
cial international threshold limits for alcohol concentration 
in blood when driving, standardized analytical methods to 
determine breath alcohol concentration at roadsides and 
blood alcohol levels at emergency departments. In the last 
twenty years, awareness of road safety and psychoactive  
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drug use has been increased, due to the evidence that these 
substances have the ability to affect the correct functioning 
of the central nervous system and may impair driving skills 
(e.g. attention, time estimation, reaction time). Starting from 
1999, several international research projects have been per-
formed to investigate various aspects of psychoactive drugs 
and driving. Roadside surveys, self-reported questionnaires 
or interviews as well as epidemiological studies have in-
volved both the general driving population and specific sub-
sets of drivers to detect the different prevalence of drugs. It 
should be considered that direct comparison between differ-
ent studies is difficult to achieve, because of the different 
approaches involved and considered parameters such as the 
time of sampling (e.g. daytime or night-time), biological 
matrix chosen for analysis (e.g. blood, oral fluid, urine), 
sample devices for collection, and also selected drugs and 
their cut-offs [2]. Recent studies have reported that the 
prevalence of drug use among drivers ranges from 3.9 to 
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20.0% [3, 4], and among fatally injured people in a road traf-
fic crash from 8.8% to 33.5% [3, 5]. Drugs relevant to im-
paired driving include prescription drugs (e.g. benzodiazepi-
nes, opioid analgesics, antidepressants), illicit psychotropic 
drugs (e.g. cocaine, heroin, amphetamines, cannabis), and 
new psychoactive substances (e.g. synthetic cannabinoids or 
cathinones). Cannabis, cocaine, amphetamines, and opiates 
are the most detected drugs in general driving population [6]. 
In addition, a recent systematic review and meta-analysis of 
66 international studies concluded that the use of ampheta-
mines, benzodiazepines, cannabis, cocaine and opiates was 
associated to a higher risk of a fatal road crash [7]. Similarly, 
the “World Health Organization report on road safety” 
showed that amphetamine is responsible for 51% drug-
related road traffic deaths, followed by cannabis (22%), co-
caine (14%) and opioids (13%) [1]. Measures to reduce drug 
induced road injuries have been introduced worldwide, and 
involve awareness-raising about drug-driving injury, law 
provisions and their enforcement together with drug testing 
at roadside [8]. Blood is the matrix of choice for drug con-
firmation and quantification analysis in driving under the 
influence of drugs cases, due to a good correlation with 
pharmacologic effects of the drug at the central nervous sys-
tem. Cut-offs for blood concentrations have been proposed 
by different countries and bodies [9, 10] and recently a com-
parison between different proposals evidenced great interna-
tional inhomogeneity [11]. 
 Since the 1970s, oral fluid (OF) has been studied as an 
alternative sample matrix to disclose current consumption of 
psychotropic drugs [12-16] and recently its use has been 
proposed as on-site test at roadside to identify drivers under 
the influence of drugs[17-19]. The main advantages of oral 
fluid are the easy and non-invasive sample collection, more 
difficult adulteration of the sample, and a lower infection 
risk compared to blood collection. Passage of drug molecule 
from blood to OF is created primarily by passive diffusion 
that depends on several physicochemical factors, such as: pH 
of blood and OF, pKa and lipid-solubility of the drug, its 
molecular weight, fraction bound to plasma proteins and 
salivary flow rate. As only unbound or free drugs are ex-
creted into the oral fluid, there is evidence for some drugs 
that OF concentrations correlate with free drug plasma con-
centrations, so OF may better reflect recent drug use, provid-
ing a better correlation with pharmacodynamics effects, such 
as impaired performances. Limitations associated with OF 
testing include the difficulty in collecting proper volume, 
oral cavity contamination after oral or smoked administra-
tion and dry mouth following cannabis or stimulant drugs 
use [20, 21]. The performance of OF testing when driving 
under the influence of drugs is yet to be investigated in sys-
tematic studies [10, 19, 22-24]. Moreover major gaps exist, 
ranging from the relationship between drug concentration in 
oral fluid and blood, cognitive impairment and crash risk, 
standardized analytical methods and appropriate drug cut-off 
associated to alteration in driving skills. 
 Nevertheless, due to several advantages of OF testing 
(eg. on site testing at the roadsite, non- invasive collection 
not requiring skilled personnel, possibility to collect a sec-
ond sample for laboratory confirmation), quite recently this 
matrix has been introduced in place of blood. 
 In this scenario, we sought to review international studies 
on correlation between blood and oral fluid drug concentra-
tions, neurological correlates and cognitive impairment in 
driving under the influence of drugs. 
METHODS 
 Relevant scientific articles were identified from PubMed, 
Cochrane Central, Scopus, Web of Science, Science Direct, 
EMBASE up to April 2017 using the following keywords: 
“cannabis”, “marijuana”, “heroin”, “cocaine”, “ampheta-
mines”, “amphetamine-type stimulants”, “new psychoactive 
substances”, “driving under the influence”, “cognitive im-
pairment”, “neurocognitive correlates”, “acute cognitive 
effects”, “chronic cognitive effects” and “toxicological 
analysis”. The main keywords were individually searched in 
association with each of the others. The papers not suitable 
for the purpose of the review were excluded; hand search 
was performed through the reference-lists of the included 
articles. 
RESULTS 
 The experimental studies investigating the psychoactive 
effects of drugs on neurological performances, and how 
these effects correlate with blood and/or oral fluid concentra-
tions and with driving impairment, have been reported for 
each psychotropic drug or class of drugs. Table 1 shows 
blood and oral fluid psychoactive drug concentrations related 
to cognitive impairment parameters in driving under the in-
fluence of drugs. 
CANNABIS 
 Cannabis is a natural drug, consisting of the dried flower-
ing, fruiting tops and leaves of the Cannabis sativa plant. 
Hashish is the dried resinous secretion of the plant, and can-
nabis oil is a solvent extract of cannabis. The main psy-
choactive substance is tetrahydrocannabinol (THC), which is 
highly lipophilic and can be distributed widely in the body 
[25]. Acute and chronic use of cannabis has been shown to 
impair psychomotor functions, memory and attention, often 
in a dose dependent manner [26, 27]. Since the ’70 of the last 
century, experimental investigations have assessed the ef-
fects of cannabis on neurocognitive functions necessary in 
normal driving tasks [28]. Both acute and chronic use of 
cannabis has been linked to affect driving skills such as mo-
tor control, psychomotor speed, executive function, motor 
impulsivity, manual dexterity, visual processing, short-term 
memory, working memory, perception and balance [29-31]. 
Cognitive impairment following THC smoking can be de-
tected several hours after its use; e.g, in healthy volunteers, 
memory impairment persists for about 10 hours after the 
administration of 15 mg of THC [32]. Recent studies showed 
that chronic users of cannabis often present a long-term cog-
nitive impairment that may persist even after a period of ab-
stinence [26, 33, 34]. In a recent meta-analysis, cannabis use 
was found to be associated with a higher relative risk (RR) 
of being involved in fatal (RR 1.25) or injury (RR 1.08) road 
accidents [7]. 
 Even if THC blood concentrations do not directly  
correlate with those in the brain responsible for cognitive 
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Table 1. Blood and oral fluid psychoactive drug concentrations related to cognitive impairment parameters in Driving Under the 
Influence of Drugs. 
Psychoactive  
Substance 
Impairment Parameters 
Reported 
Blood  
Concentration 
Impairment  
Correlation 
Oral fluid  
Concentration 
and OF/B 
Impairment  
Correlation 
Refs. 
Cannabis (THC) 
Critical tracking task  
(perceptual motor control) 
Stop signal task (motor 
impulsivity) 
Tower of London task 
(cognition and judgment) 
 0 - >30 ng/ml 
Critical tracking task: 
p=0.026, R=-0.13 
Stop signal task: 
p<0.001, R=0.32 
Tower of London task: 
p<0.001, R=-0.38 
10-30 folds 
higher than se-
rum THC (OF/B 
p<0.001, R= 
0.84) 
Critical tracking task: 
p=ns, R=-0.18 
Tower of London 
task: p=0.006,  
R=-0.35 
[37] 
Cannabis (THC) 
31 signs of impairment 
(attitude, body appearance, 
facial expression, speech, 
coordination, and eye signs) 
Not tested Not tested 
≤ 3.00 - >100 
ng/mL 
OR 1.70 (THC ≤ 3.00 
ng/mL), 3.78 (THC 
3.01-25.00 ng/mL), 
7.22 (THC 25.01-100 
ng/mL), 16.55 (THC 
<100ng/mL) 
[47] 
Ampheta-
mine/Methampheta
mine 
Clinical test for impairment 
(CTI, 25 tests related to 
common signs of drug 
impairment) 
Median  
amphethamines 
concentration 
0.53 mg/l 
(range 0.04-
3.74 mg/l) 
OR adjusted for age, 
gender and blood am-
phetamines concentra-
tion: 0.98 (0.96-1.00) 
Not tested Not tested [125] 
Cocaine 
Walking performance, 
speech, mood, motor coor-
dination, pupil’s state 
Not tested Not tested 
Mean: 4.12 mg/l 
M ± SD: 0.38 ± 
28.28 mg/l 
Range: 0.01-
345.64 mg/l 
No significant corre-
lation observed 
[106] 
Cannabis (THC) 
THC serum 
concentrations 
in impaired/not 
impaired users 
is reported in 
the next column 
31.9% of users were 
classified as impaired by 
both police and medical 
officers (THC in serum 
4.6 ± 4.8 µg/L, M ± SD) 
27.7% were classified as 
impaired only by police 
officers (THC in serum 
5.9 ± 4.9 µg/L) 
31.9% appeared not to 
be impaired at all (THC 
in serum 5.0 ± 5.3 µg/L) 
However a correlation of 
the THC concentrations 
with the impairment was 
not possible 
Oral fluid versus 
serum 
Accuracy 90.8% 
Positive predic-
tive value 93.0% 
Negative predic-
tive value 88.3% 
Not reported 
Opioids Not reported 
77.8% of users were 
classified as impaired by 
both police and medical 
officers. 
Opiods serum concentra-
tions not reported 
Oral fluid versus 
serum 
Accuracy 95.4% 
Positive predictive 
value 91.3% 
Negative predic-
tive value 96.3% 
Not reported 
Amphetamines 
15 signs by police  
observation 
15 signs by medical  
examination 
Not reported 
50.0% of users were 
classified as impaired by 
both police and medical 
officers. 
Amphetamines serum 
concentrations not re-
ported 
Oral fluid versus 
serum 
Accuracy 93.1% 
Positive predic-
tive value 81.4% 
Negative predic-
tive value 98.9% 
Not reported 
[50] 
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impairment [35], several studies have investigated the link 
between THC blood levels and impaired driving. Recent 
epidemiological studies have suggested that THC blood con-
centrations of 2-5 ng/ml are generally associated with driv-
ing impairment and increased accident risk [27, 36-40]. Pro-
posed cut-offs for THC blood concentration range from 1 to 
5 ng/ml [11] but several countries adopt a zero-tolerance 
policy that does not allow the presence of any amount of 
THC in blood while driving. Nevertheless, a significant cor-
relation between THC blood concentrations and drivers im-
pairment is still lacking mainly due to the complex pharma-
cokinetics and metabolism of THC and the inter-individual 
variability in blood concentrations of consumers of similar 
doses [37]. Moreover, it should be considered that the results 
of studies on the driving effects of cannabis use have been 
related to the investigation strategies applied and to the im-
pairment parameters considered. Indeed, Battistella and co-
workers recently suggested that driving skills correlate with 
the subjective feeling of confusion rather than with the blood 
level of THC [41], while Karschner et al. supported that 
THC’s presence in blood may not correlate with its recent 
use and driving impairment since THC whole blood/plasma 
levels >1 ng/mL (range 1.2–5.5 ng/mL) could be measured 
in 50% chronic daily cannabis smokers even after 7 days of 
abstinence [42]. 
 An experimental study on performance impairment as a 
function of THC in serum and OF by Ramarkers and col-
laborators showed a strong and linear correlation between 
THC in serum and OF; however they did not find a signifi-
cant linear association between performance impairment and 
serum THC values. Nevertheless, when comparing the pro-
portion of observations showing impairment or no impair-
ment as a function of THC concentration, impairment was 
found to progressively increase as a function of serum THC 
in every performance task. Subsequently, at THC concentra-
tions between 5 and 10 ng/ml, approximately 75–90% of the 
observations showed a significant impairment in every per-
formance test. From all the gathered information, it was con-
cluded that serum THC concentrations between 2 and 5 
ng/ml represent the lower and upper range of THC limit for 
impairment [37]. 
 With respect to OF, the possibility to predict the preva-
lence of blood THC concentrations above the chosen limits 
in a population by analysing oral fluid was investigated. 
Equivalent cut-off thresholds could be estimated in a regres-
sion model with concentration percentiles in OF as depend-
ent variables and the corresponding concentration percentiles 
in blood as independent variables. The authors used paired 
OF and blood samples to determine accurate regression for-
mulae for THC cut-off concentrations in oral fluid corre-
sponding to 2.0, 4.0, 6.0, 8.0 and 10.0 ng/ml in blood. The 
accuracy was better than 100 ± 20% in comparison to actual 
prevalence in blood. However, the authors highlighted that 
the regression formula could be influenced by some factors, 
as the number of samples investigated, the oral fluid sam-
pling method, and the time between cannabis smoking and 
sampling. [43,44]. 
 Finally, several studies tried to establish fixed ratios be-
tween the THC concentrations in oral fluid and blood and 
between oral fluid THC and driving impairment. Although 
some correlations have been described, large inter-individual 
variations in THC OF/ blood ratio have been reported, along 
with as a weak relationship between performance impair-
ment and THC oral fluid concentration. Eleven -hydroxy- 
delta (9)-tetrahydrocannabinol (11-OH-THC) and 11-nor-9-
carboxy-delta-9-tetrahydrocannabinol, (THC-COOH) must 
be measured in biological specimens in addition to THC. If 
both metabolites are present, it indicates that cannabis was 
consumed more recently and motor impairment may still be 
present [37, 45-53]. 
OPIOIDS 
 Opioids are primarily used as licit drugs in the treatment 
of moderate to severe pain [54, 55]. At the same time, both 
natural, synthetic and new synthetic opioid (e.g. fentanyl and 
derivatives) are a class of psychotropic substances that are 
widely mistreated [56, 57]. Cognitive functions and psycho-
motor abilities have been moderately affected by opioids’ 
use, although the effects vary between different molecules 
and are generally most pronounced during the first few days 
after starting opioid therapy, before tolerance develops [58, 
59]. An early studies of this century by Zacny et al. tested 
psychomotor and cognitive performance following the ad-
ministration of commonly prescribed opioids to healthy, 
opioid naive subjects finding no evidence of statistically sig-
nificant impairment with respect to placebo-administered 
subjects [60-62]. 
 In a 2011 published meta-analysis, a single dose of mor-
phine of up to 5 mg has been shown to cause only very few 
effects on driving performances tasks whereas higher doses 
corresponded to alteration of various tasks, but no clear di-
rect dose-effect relationship was observed. Differently, sin-
gle dose of methadone up to 10 mg impaired performance of 
drug-naïve, healthy subjects, but these effects were less pro-
nounced in opioid users [63]. 
 Concerning codeine, another driving simulator study 
showed that 120 to 270 mg daily use of this natural opioid 
does not impair driving abilities in patients with chronic pain 
[64]. Conversely, chronic heroin users showed impairment 
of planning function [65], reaction time [66], time perception 
[67], spatial working memory [68], executive functioning 
[68-70], and right-left discrimination [71] with some of these 
impaired skills persisting for more than 1 year after cessation 
of the drug’s use [72]. 
 Apart from these investigations carried out on driving 
simulators, international literature reports some epidemiol-
ogical studies on the risk of it being involved in a traffic ac-
cident while driving under the influence of opioids. In-
creased accident relative risks were observed when driving 
under the influence of any opioid alone (morphine, heroin, 
codeine or methadone) [38, 73-75]. A recent control case 
study based on data from nine European countries estimated 
a moderate increased relative risk (RR 2-10) of serious in-
jury when driving under the influence of medicinal or illicit 
opioids [76]. 
 OF gave an excellent alternative biological matrix for 
opioids detection in case of driving under the influence of 
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these drugs. The biomarker of heroin consumption, 6-
monoacetylmorphine (6-MAM), can be easily found in oral 
fluid [77], providing a useful tool for screening of opioids 
consumption at the roadside [10, 78, 79]. It is known that 
within a few minutes after intake, heroin is metabolized to 6-
MAM and then further to morphine [77]. The short half-life 
makes 6-MAM only detectable for a short time, and it is 
rarely found in blood or urine. Its presence in oral fluid can 
be used to differentiate heroin use from the consumption of 
morphine alone or codeine in drivers suspected of opioids’ 
use [10]. 
 In another work, by Langel and collaborators, the median 
OF/B ratios for codeine (4.8), methadone (1.8), morphine 
(6.4) and tramadol (1.1) were found to be close to theoretical 
values based on the physicochemical properties of the drugs, 
and a statistically significant correlation between OF and 
blood concentrations was observed. However, some cases 
were only positive in oral fluid; most of them have been ex-
plained by the low concentration of the analyte in the OF 
sample, and due to longer detection times in the OF with the 
cut-offs used, the corresponding lower blood concentrations 
might not have been detected [51]. 
 Toennes and collaborators found more than 90% accu-
racy in correlating opioids’ detection in oral fluid and serum. 
Moreover, impairment symptoms considered in the study 
were detected in all the opioid user group both by police 
officers at the time of the offence and by medical officer at 
the time of sampling [80]. 
 In North America (US and Canada), there is an epidemic 
of the abuse of prescribed opioids, e.g. fentanyl, oxycodone 
or hydrocodone. With respect to these substances, some 
studies have been performed. 
 For example, it has been found that fentanyl in concen-
trations used in surgical procedures (0.2 µg/kg) produced 
pronounced cognitive impairment (auditory reaction time, 
signal detection, sustained attention, recognition) when com-
pared with placebo [81]. Similarly, attention, reaction, visual 
orientation, motor coordination and vigilance were not af-
fected by the long-term use of transdermal fentanyl in pa-
tients with continuous non-cancer pain [82,83]. 
 Several investigations in different countries agreed that 
psychomotor functioning, crucial for safe driving, was not 
impaired in patients with chronic pain receiving effective 
pain relief with controlled release oxycodone therapy [84-
87]. 
 Likewise, a modest psychomotor impairment has also 
been shown with increasing (0, 0.33, 0.65, 1.3 mg/70 kg) 
intravenous hydromorphone in non-drug-abusing volunteers 
[88]. This study has been subsequently confirmed by Byas-
Smith et al., [89], who evidenced that many patients with 
chronic pain, even if treated with potent analgesics such as 
morphine and hydromorphone, show comparable driving 
ability as normals. 
 Finally, a very recent systematic review of experimental 
studies to define blood opioid concentrations related to im-
pairment in opioid-naïve subjects concluded that plasma 
morphine concentration of 14.3 ng/ml could represent at a 
threshold concentration, under which there is little related 
road traffic risk. A single dose of 5 mg intravenous morphine 
and analgetic equivalence doses of fentanyl, hydromorphone, 
oxycodone and oxymorphone did not present traffic-relevant 
effects [90]. 
COCAINE 
 Cocaine, the psychoactive drug extracted from the leaves 
of Erythroxylum Coca shrub, is the most popular drug of 
abuse in Europe after cannabis. It belongs to the group of 
“stimulant drugs”, increasing mood and feelings of well-
being, energy and alertness [91]. Only few experimental 
studies investigated cognitive effects of acute cocaine use in 
naive users especially due to ethical issues since cocaine 
shows a considerable risk of addiction [92]. Hence, few sys-
tematic studies investigated the eventual driving ability un-
der the influence of this drug. 
 Acute cocaine administration in users seems to improve 
response inhibition and a speed component in psychomotor 
tasks but only when intranasally administered [93-97]. Long 
term cocaine use has been associated with impairment in 
sustained attention, visuospatial perception, cognitive flexi-
bility, response inhibition, memory and psychomotor per-
formances [91, 98-101]. In agreement with the previous con-
trolled observations, epidemiological studies demonstrated 
that cocaine may increase the risk of being involved in driv-
ing accidents [76, 102, 103]. In a meta-analysis carried out 
by Elvik et al. in 2013, the best estimate of the relative risk 
of accident involvement with cocaine was 2.96 (95 % CI 
1.18–7.38) for fatal accidents, 1.66 (95 % CI 0.91–3.02) for 
injury accidents and 1.44 (95 % CI 0.93–2.23) for crashes 
resulting in property damage [7]. 
 In 370 fatally injured drivers in Washington State, the 
mean and median blood cocaine concentrations were 0.72 
mg/l and 0.31 mg/l, respectively (range <0.01- 1.08 mg/l) 
[104]. Similarly in 1425 German drivers under suspicion of 
driving under the influence of psychoactive drugs, mean and 
median blood value for cocaine were 0.836 mg/l and 0.379 
mg/l (range 0. 005-2 mg/l), respectively [105]. In 1791, 
Spanish drivers who were tested as positive for cocaine with 
mean and median cocaine concentration of 4.12 mg/l and 
0.38 mg/l (range 0.01-345.64 mg/l), respectively, clinical 
impairment symptoms such as motor coordination, walking, 
speech, mood and state of pupils were not significantly cor-
related with cocaine concentrations [106]. Proposed cut-off 
values for cocaine in blood range from 10 up to 80 ng/mL 
depending on different international studies as reported by 
Busardò and collaborators [11]. 
 The correlation between OF and blood cocaine concen-
trations is still not well established. Cocaine is a weak base 
and is subject to OF ion trapping; however the use of cocaine 
leads to reduced salivary volume (dry mouth), and abuse of 
smoked crack cocaine, insufflation of cocaine hydrochloride, 
and oral cocaine abuse can lead to a contamination of the 
oral cavity resulting in high initial OF levels compared to 
concentrations that occur after intravenous cocaine admini-
stration [12]. In controlled administration studies, cocaine 
was identified in OF after smoking, intravenous, intranasal 
and oral administration [107-109]. After subcutaneous ad-
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ministration, cocaine was identified in OF 0.08-0.32 h after 
dosing, with a half-life of 1.1-3.8 h; the correlation between 
cocaine OF and blood concentrations was significant, al-
though no correlation with clinical symptoms was described 
[110]. A cocaine OF/Blood ratio of 22 (range 4-119) was 
reported in a sample of people driving under suspicion of 
drugs [52] and a similar OF/blood ratio value (17) was also 
obtained by Langel and collaborators [51]. These data indi-
cate that OF is a good alternative biological matrix to test 
cocaine use at the roadside or in drivers involved in car 
crashes, providing an immediate evidence of driving under 
the influence of this psychostimulant drug. 
 Cocaine can partially diminish performance impairments 
caused by alcohol consumption. The use of a combination of 
alcohol and cocaine decreases psychomotor impairment and 
improves performance on cognitive tests when compared 
with the use of alcohol alone [111,112]. Cocaine use also 
reduces the subjective feeling of drunkenness caused by al-
cohol [111,112]. Chronic use of alcohol or cocaine selec-
tively affects performance on different neurobehavioural 
tests in a dose-dependent way [113]. However, their com-
bined use may not cause additional negative effects on the 
brain, as subjects addicted to only cocaine demonstrate simi-
lar or greater neurocognitive impairments than those who 
abuse both alcohol and cocaine [114-116]. 
AMPHETAMINES 
 Amphetamine and amphetamine-type substances such as 
methamphetamine and 3,4-methylendioxymethamphetamine 
(MDMA, ecstasy) are most commonly abused due their 
stimulant effect on the central nervous system, that results in 
sociability enhancement, increased mood, auditory and/or 
visual perceptions, and energy boosting as reported by rec-
reational users during controlled administrations or recrea-
tional settings (discos, dance parties, sex parties and raves) 
[117-110]. Acute or chronic use of amphetamines has been 
implicated in increased dangerous driving, with an estimated 
relative risk of 8.67 (95% CI 3.23 - 23.32) for crashes result-
ing in property damage, 6.19 (95% CI 3.46 - 11.06) for in-
jury accidents, and 5.17 (95% CI 2.56 - 10.42) for fatal acci-
dents [7]. In contrast with the above reported data, experi-
mental studies showed that amphetamines like MDMA, 
methamphetamine and dexamphetamine, can improve cer-
tain aspects of cognitive/driving performances, while impair-
ing other aspects at the same time. Skills such as tracking, 
impulse control and reaction time can be generally improved, 
whereas cognitive functions such as working memory and 
movement perception can be impaired [121-123]. Neverthe-
less, there is a limitation in these experimental investiga-
tions: doses used are not representative of the doses con-
sumed by users in real-life scenarios. 
 High dose effect of amphetamines on driving perform-
ances cannot be assessed because of medical and ethical con-
straints, and concentrations of amphetamines in the blood of 
subjects driving under the influence of these drugs have been 
reported about or above 10-fold higher than those used in 
experimental studies [124]. Blood cut-off values for am-
phetamines have been recently proposed, ranging from 20 to 
600 ng/mL for amphetamine, from 20 to 200 ng/mL for 
methamphetamine, and from 20 to 300 ng/mL for MDMA [11]. 
 Gustavsen and collaborators investigated the concentra-
tion-effect relationship between blood amphetamine levels 
(range 0.04 - >1.00 mg/l) and impairment in 878 cases with 
amphetamine as the only drug present in the blood samples 
of impaired drivers. 73% of cases were judged as impaired 
and a significant positive concentration-effect relationship 
was found, with a ceiling effect above 0.27-0.53 mg/l [125]. 
 Amphetamines are lipid-soluble, weakly basic drugs with 
high pKa and low plasma-protein-binding, and can be de-
tected in oral fluid, generally with oral fluid concentrations 
several times higher than in blood. Recent studies showed 
the possibility of estimating the prevalence of blood am-
phetamine concentrations above the chosen limits in a popu-
lation by analysing oral fluid. In addition, equivalent cut-off 
thresholds could be estimated using a regression model with 
concentration percentiles in the OF as the response variable 
and the corresponding concentration percentiles in blood as 
the predictor variable. They used paired OF and blood sam-
ples to determine accurate regression formulae to calculate 
amphetamine cut-off concentrations in oral fluid correspond-
ing to 200, 400, 600, 800 and 1000 ng/ml in blood; the accu-
racy was better than 100 ± 20% compared to the actual 
prevalence in blood. However, the authors highlighted that 
the regression formula could be influenced by some factors, 
as the number of samples investigated, the oral fluid sam-
pling method and the time between consumption and sam-
pling. [43, 44]. 
 A significant OF/B correlation has been found in several 
studies [10, 51, 52, 126]; it was also reported that when simi-
lar detection cut-off values were used for both oral fluid and 
blood, some positive amphetamines samples were missed 
when analysing only the blood specimen, due to the larger 
detection time window in oral fluid and/or oral contamina-
tion [127, 128]. To the best of our knowledge, there are no 
studies investigating the relationship between amphetamines 
in OF and impairment signs associated to driving. 
NEW PSYCHOACTIVE SUBSTANCES 
 New psychoactive substances (NPS) are generally re-
ported as substances that are “not specifically controlled un-
der the existing legislation, with the capacity to stimulate or 
depress the central nervous system resulting in hallucina-
tions, dependence or significant changes to motor function, 
thinking or behaviour”[129, 130]. 
 NPS are also known and sold under the names of “legal 
highs”, “bath salts”, ”herbal highs”, and “research chemi-
cals”; most of them are not regulated through the Interna-
tional Drug Control Convention so that their legal status is 
differently settled in each country. 
 First classes of NPS were represented by cathinones, 
phenethylamines, tryptamines, piperazines, and synthetic 
cannabinoids molecules, recently followed by aminoindanes, 
arylalkylamines and arylcyclohexylamines molecules [131]. 
These substances are mainly sold over the Internet and de-
spite the numerous reports, mainly by the users themselves, 
about the effects, pharmacology of NPS is not well known. 
In addition, knowledge regarding the potential toxic and le-
thal concentrations of these drugs after ingestion is absent 
for the majority of the different substances [132-134]. As 
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previously mentioned, all the drugs that affect the CNS – 
whether prescribed or illegal drugs – may cause driving  
impairment by affecting crucial driving skills such as the 
reaction time, judgment and processing simultaneous tasks 
[135]. 
 Driving under the influence of drugs has a major detri-
mental impact on traffic all over the world and the problems 
of driving under the influence of NPS constitute at the mo-
ment an open research area. Some investigators support the 
idea that since on site tests are still not able to detect NPS, it 
is not possible to exclude the presence of NPS in a driver 
even if the test at roadside shows a negative result to alcohol 
and classic psychotropic drugs [136]. 
 Synthetic cathinones are the most frequently detected 
NPS in Europe together with synthetic cannabinoids. Not-
withstanding this fact, the only cathinone investigated for its 
impact on driving has been alpha-pyrrolidinovalerophenone 
(α-PVP). This synthetic stimulant has been identified as the 
cause of a traffic accident involving the driver and four pas-
sengers. Variable concentrations of α-PVP were detected in 
blood samples of all individuals, ranging from 230-360 
ng/ml for n. 3 surviving subjects and 290-650 ng/ml for the 
two deceased individuals [137]. 
 Adamowicz and collaborators reported α-PVP blood lev-
els of 9 drivers using exclusively this drug; a mean concen-
tration of 20 ng/ml was not associated to any impairment 
sign, whereas a mean concentration of 39 ng/ml was associ-
ated to staggering, unsteady gait, confusion, and slurred 
speech. In 14 drivers, α-PVP has been detected in blood to-
gether with other drugs, but with mean concentrations simi-
lar to α-PVP-only cases (28 ng/ml for drivers with observed 
symptoms, and 38 ng/ml for drivers without symptoms) 
[138]. 
 Synthetic cannabinoids are also frequently consumed 
NPS due to their marijuana-like effect; they are available as 
herbal products sprayed with these molecules that have been 
shown to be functionally similar to THC [139]. 
 To date, synthetic cannabinoids are not included in any 
specific road legislation; their prevalence in DUID cases is 
arising and international studies have reported the associa-
tion between positive chemical–toxicological analysis and 
various signs of impairment. 
 In 2014, Musshoff and collaborators reported several 
DUID cases involving synthetic cannabinoids. Drivers were 
found impaired by the police or medical personnel; toxico-
logical analysis in blood allowed the identification and quan-
tification of several synthetic cannabinoids, as AM 2201 
(concentration range 0.31 - 4.6 ng/ml), JWH-018 (concentra-
tion range 0.17 - 1.9 ng/ml), JWH 210 (concentration range 
0.66 - 6.2 ng/ml), JWH122(0.26 - 28ng/ml), JWH-019 (con-
centration 1.7 ng/ml), and JWH-307 (concentration 1.1 
ng/ml) [140]. 
 Other synthetic cannabinoids of newer chemical classes 
have been measured in the blood of six impaired drivers one 
year later by Karinen et al. UR-144 levels were 0.22 mg/l and 
0.47 mg/l in two drivers; 5F-APINACA level was 5.3 mg/l  
 
in one case, whereas concentrations of 0.9 mg/l, 6.5 mg/l, 
and 2.2 mg/l were detected in three drivers together with 
APINACA concentrations of 2.2 mg/l, 0.24 mg/l, and 24.5 
mg/l respectively. 
 In addition, AM-2201, a synthetic cannabinoid of first 
generation, was detected in blood samples of three drivers 
with concentrations ranging between 0.11 and 0.13 mg/l, 
close to previously reported ranges [132]. 
 A potential reduction in driving abilities in subjects con-
suming synthetic cannabinoids has been proposed, since im-
pairment signs as a delayed reaction of pupils to light, 
blurred speech, dizziness, instable appearance and retarded 
sequence of movements have been detected in these users 
[141]. 
 Another important class of NPS is phenethylamines. The 
consumption of these compounds can lead to psychic altera-
tions similar to those observed after the use of amphetamine 
or amphetamine-type substances such as MDMA, including 
different neurological and psychological symptoms which 
can affect a safe driving behaviour. 
 In a road accident involving a driver and one passenger, 
the phenethylamine 2C-B was detected at blood concentra-
tions of 1.6 and 14 ng/ml, together with amphetamine levels 
of 23 and 38 mg/ml, respectively [131]. 
 Methoxetamine, a dissociative drug that has been sold as 
a new designer drug, is a non-competitive NMDA receptor 
antagonist, reuptake inhibitor of different neurotransmitters 
[142]. This is also one of the NPS detected in the blood (10 ± 
0.3 ng/ml, M ± SD) of a car driver with a polydrug intoxica-
tion who presented a compromised ability in controlling the 
motor vehicle [143]. A recent work indicates that the range 
of blood concentrations of methoxetamine in living indi-
viduals is similar in the U.S.A. and Europe (0.2– 0.5 ng/ml), 
despite the consumed dosage was unknown. A high 
methoxetamine level (8.6 ng/g) was found in a femoral blood 
sample in a post-mortem case [144]. 
 Fassette and collaborators described a case of a female 
subject driving a vehicle under the effect of acute intoxica-
tion after ingesting methoxetamine earlier in the day. Loss of 
legs control, difficulty in talking, confusion and excessive 
sweating were present. Screening of the blood sample 
showed positivity for amphetamines and confirmation analy-
sis by GC/MS revealed methamphetamine (90 ng/ml), am-
phetamine (20 ng/ml), dextromethorphan (20 ng/mL) and 
methoxetamine at the concentration of 151 ng/mL [145]. 
 A major observation can be made on impaired driving 
and NPS: to date, the lack of analytical data, pure standards, 
and studies on impaired performances following consump-
tion, make NPS detection a major toxicological challenge. 
Although few data exist for NPS measurement in blood, no 
international literature exists regarding the determination of 
these substances in oral fluid at the roadside. Although this 
biological matrix has been demonstrated for many basic 
drugs to more closely mimic the time course of detection in 
the whole blood, no epidemiological data could verify if this 
could be true for NPS. 
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CONCLUSION 
 Driving is a complex task where the driver continuously 
elaborates and responds to information received from the 
external surround; so it is clear that driving performance can 
be influenced by any substance able to influence brain func-
tions and/or mental processes. Multiple aspects of driving 
performance can be differently affected by illicit drugs, and 
even if for few of them, some dose/concentration dependent 
impairment has been reported, a wider knowledge on con-
centration/impairment relationship is still missing. 
 Blood is the matrix of choice when investigating DUID 
cases [52, 146] due to its detection time-window, and for 
most drugs, it has been shown a good correspondence with 
the oral fluid matrix. 
 It is well known that the passage of a drug from blood to 
oral fluid, reported as the concentration ratio between oral 
fluid and blood (OF/B ratio), is determined principally by 
some physicochemical properties of the molecule (pKa, pro-
tein binding, lipophilicity, molecular weight and spatial con-
figuration) [21]. 
 Although OF/B ratios of many drugs have been theoreti-
cally calculated, experimental studies have showed signifi-
cant inter- and intra-subject variability in OF/B ratios, even 
when collecting OF in a controlled manner, making the esti-
mation of drug concentrations inaccurate in blood from its 
concentrations in oral fluid. 
 Different classes of drugs have been found in the blood 
of drivers, with cannabis, cocaine, opiates, and ampheta-
mines representing the most prevalent in the EU countries 
[147]. 
 Efficient and reliable on-site tests to detect drivers under 
the influence of drugs are continuously developed. Roadside 
testing using urine sample is usually performed but it is time-
consuming and has the risk of infections and potential dis-
ease transmission. OF testing has also been proposed as an 
alternative to blood and has shown its feasibility in roadside 
studies [138, 139, 148-152]. 
 However, different studies underlined that a reliable cor-
relation of pharmacologic effects can only be based on 
blood/serum concentrations as oral fluid concentrations are 
elevated shortly after drug-use because of contamination of 
the oral cavity [21, 48, 147] and the complexity in defining 
fixed OF/B ratios, that makes oral fluid drug concentration 
an inappropriate tool for impairment evaluation [52, 148]. 
Finally, the difficulties of testing some drugs independently 
of the biological matrix on-site have made some programs  
to include blood testing for very specific drugs. This ap-
proach will be of relevance in the future for controlling NPS 
misuse. 
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